Primary Clinical Response of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma (r/r FL) in China

被引：0
作者：
Song, Yuqin [1 ]
Ying, Zhitao [1 ]
Yang, Haiyan [2 ]
Guo, Ye [3 ]
Li, Wenyu [4 ]
Zou, Dehui [5 ,6 ,7 ]
Wu, Jianqiu [8 ]
Yang, Su [9 ]
Zhang, Pian [9 ]
Ma, Meilin [9 ]
Zhou, Zisong [9 ]
Zheng, Hongxia [9 ]
Zhu, Jun [1 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
[2] Chinese Acad Sci, Inst Canc & Basic Med IBMC, Dept Med Oncol, Hangzhou, Peoples R China
[3] Shanghai Dongfang Hosp, Tongji Univ, Dept Med Oncol, Shanghai, Peoples R China
[4] Guangdong Acad Sci, Dept Lymphoma, Guangdong Provincial Peoples Hosp, Guangzhou, Guangdong, Peoples R China
[5] Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Blood Dis Hosp, Tianjin, Peoples R China
[6] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
[7] Peking Union Med Coll, Tianjin, Peoples R China
[8] Affiliated Hosp Nanjing Med Univ, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Dept Med Oncol,Jiangsu Red Cross Canc Ctr, Nanjing, Peoples R China
[9] JW Therapeut Shanghai Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-150085
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2434
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)
    Palomba, M. Lia
    Ghione, Paola
    Patel, Anik R.
    Deighton, Kevin
    Jacobson, Caron
    Nahas, Myrna
    Jung, A. Scott
    Hatswell, Anthony J.
    Kanters, Steve
    Limbrick-Oldfield, Eve
    Wade, Sally W.
    Snider, Julia Thornton
    Neelapu, Sattva S.
    Riberio, Maria Teresa
    Gribben, John
    Radford, John
    Bobillo, Sabela
    Ghesquieres, Herve
    BLOOD, 2021, 138
  • [42] Assessment of durable responses after brexucabtagene autoleucel (brexu-cel) in relapsed/refractory mantle cell lymphoma (R/R MCL)
    Pindoria, Lohit
    Munoz, Javier
    Reagan, Patrick
    Goy, Andre
    Miklos, David
    Zheng, Dan
    Fang, Xiang
    Shen, Rhine
    Siddiqi, Rubina
    Kloos, Ioana
    Kersten, Marie Jose
    Wang, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 113 - 114
  • [43] Tazemetostat in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Propensity Score-Matched Analysis of E7438-G000-101 Trial Outcomes
    Proudman, David
    Gupta, Deepshekhar
    Nellesen, Dave
    Wong, Alex
    Yang, Jay
    Kamp, Beth
    Mamlouk, Khalid
    Cheson, Bruce
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S403 - S403
  • [44] A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Third-or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)
    Matasar, Matthew
    Alvarez, Javier Sanchez
    Parise, Helene
    Zuk, Eric
    Di Maio, Danilo
    Shapouri, Sheila
    Kim, Eunice
    Lin, Shih-Wen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S455 - S456
  • [45] Phase 1 study of the safety and efficacy of INCB050465 combined with obinutuzumab and bendamustine for relapsed or refractory (R/R) follicular lymphoma (FL) (CITADEL-102).
    Coleman, Morton
    Salar, Antonio
    Munoz, Javier
    Galanina, Natalie
    Faivre, Thea
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] A COST-EFFECTIVENESS ANALYSIS OF MOSUNETUZUMAB FOR TREATMENT OF THIRD- OR HIGHER-LINE RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) IN THE UNITED STATES (US)
    Matasar, M.
    Alvarez, Sanchez J.
    Parise, H.
    Zuk, E.
    Di Maio, D.
    Shapouri, S.
    Lin, S. W.
    VALUE IN HEALTH, 2023, 26 (06) : S153 - S153
  • [47] Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory ( R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial.
    Ghosh, Nilanjan
    Salles, Gilles A.
    Lossos, Izidore S.
    Palomba, Maria Lia
    Mehta, Amitkumar
    Casasnovas, Olivier
    Stevens, Don A.
    Katakam, Sudhakar
    Knapp, Andrea
    Nielsen, Tina
    Morschhauser, Franck
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study
    Thieblemont, Catherine
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason P.
    Ghosh, Monalisa
    Popplewell, Leslie L.
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Ho, P. Joy
    Perez-Simon, Jose
    Chen, Andy
    Nastoupil, Loretta
    Von Tresckow, Bastian
    Ferreri, Andres J. M.
    Teshima, Takanori
    Patten, Piers E. M.
    McGuirk, Joseph P.
    Petzer, Andreas
    Offner, Fritz
    Viardot, Andreas
    Zinzani, Pier Luigi
    Malladi, Ram
    Zia, Aiesha
    Bodoni, C. Lobetti
    Masood, Aisha
    Schuster, Stephen J.
    Fowler, Nathan H.
    Dreyling, Martin H.
    BLOOD, 2021, 138
  • [49] Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial.
    Zinzani, Pier Luigi
    Mayer, Jiri
    Auer, Rebecca
    Bijou, Fontanet
    De Oliveira, Ana C.
    Flowers, Christopher
    Merli, Michele
    Bouabdallah, Krimo
    Ganly, Peter S.
    Johnson, Roderick
    Yuen, Sam
    Kingsley, Ed
    Tumyan, Gayane
    Assouline, Sarit E.
    Ivanova, Elena
    Pil, Kim
    Huang, Jane
    Delarue, Richard
    Trotman, Judith
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
    Falchi, Lorenzo
    Leppa, Sirpa
    Wahlin, Bjorn E.
    Nijland, Marcel
    Christensen, Jacob Haaber
    De Vos, Sven
    Holte, Harald
    Linton, Kim M.
    Abbas, Aqeel
    Wang, Liwei
    Dinh, Minh
    Elliott, Brian
    Belada, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345